Latest filing published 13 May 2019 for Novelion Therapeutics Inc., €230. Read the official filing
This profile gathers the share dealings of Benjamin Harshbarger across 3 companies, led by Novelion Therapeutics Inc., Aegerion Pharmaceuticals, Inc. and QLT Inc/BC. The record holds 21 filings, for trades running from 1 April 2016 to 9 May 2019.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 13 May 2019, the filings show a share grant worth €230 in Novelion Therapeutics Inc. Filings reach the SEDI feed a median of 2 days after the trade. Until a filing is published, the market cannot know about the trade. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations